It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Glucocorticoids (GCs) are potent repressors of NF-κB activity, making them a preferred choice for treatment of inflammation-driven conditions. Despite the widespread use of GCs in the clinic, current models are inadequate to explain the role of the glucocorticoid receptor (GR) within this critical signaling pathway. GR binding directly to NF-κB itself—tethering in a DNA binding-independent manner—represents the standing model of how GCs inhibit NF-κB-driven transcription. We demonstrate that direct binding of GR to genomic NF-κB response elements (κBREs) mediates GR-driven repression of inflammatory gene expression. We report five crystal structures and solution NMR data of GR DBD-κBRE complexes, which reveal that GR recognizes a cryptic response element between the binding footprints of NF-κB subunits within κBREs. These cryptic sequences exhibit high sequence and functional conservation, suggesting that GR binding to κBREs is an evolutionarily conserved mechanism of controlling the inflammatory response.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA; Discovery and Developmental Therapeutics, Winship Cancer Institute, Atlanta, Georgia, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA
2 Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida, USA; Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, MO, USA
3 Department of Integrated Structural and Computational Biology, The Scripps Research Institute, Jupiter, Florida, USA
4 Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA; Discovery and Developmental Therapeutics, Winship Cancer Institute, Atlanta, Georgia, USA
5 Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA
6 Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
7 Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida, USA